BusinessActinium Pharmaceuticals Announces Collaborative Research Partnership with Astellas Leveraging Actinium’s AWE Platform TechnologyBy Nasdaq OMXMar 28, 2018, 12:01 PM UTC
BusinessActinium Pharmaceuticals Announces Appointment of Jehan Rowlands, Pharm.D. as Vice-President, Head of Regulatory AffairsBy Nasdaq OMXMar 14, 2018, 11:30 AM UTC
BusinessActinium Pharmaceuticals Highlights Promising Data From its AWE Program Featuring a Potent Actinium-225 Labeled Daratumumab Labeled ARC or Antibody Radio-Conjugate Presented at ASH Annual MeetingBy Nasdaq OMXDec 12, 2017, 12:30 PM UTC
BusinessActinium Pharmaceuticals Highlights Data at the American Society of Hematology Annual Meeting Showing CD33 Expression in a Significant Number of Multiple Myeloma Patients Supporting the Rationale for Actimab-MBy Nasdaq OMXDec 11, 2017, 9:15 PM UTC
BusinessActinium Pharmaceuticals to Present at BIO Investor ForumBy Nasdaq OMXOct 16, 2017, 11:30 AM UTC
BusinessActinium Pharmaceuticals to Participate in American Society for Blood and Marrow Transplantation 2017 Corporate Council MeetingBy Nasdaq OMXSep 20, 2017, 11:30 AM UTC
BusinessActinium Pharmaceuticals Highlights Presence at the Society of Hematologic Oncology 2017 Annual MeetingBy Nasdaq OMXSep 13, 2017, 11:30 AM UTC
BusinessActinium to Present at The Rodman & Renshaw 19th Annual Global Investment ConferenceBy Nasdaq OMXSep 6, 2017, 8:05 PM UTC
